Black Diamond Director Behbahani Ali Receives 7,707-Share Award

What Happened

• Behbahani Ali, a director of Black Diamond Therapeutics, received a grant/award of 7,707 shares of BDTX common stock on 2026-09-18. The filing reports a per-share value of $1.93, giving a total reported value of approximately $14,875. The shares were issued in lieu of cash under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy.

Key Details

• Transaction date: 2026-09-18; Form 4 filed: 2026-09-21 (marked late).
• Transaction type/code: A (Award/Acquisition).
• Shares issued: 7,707 at $1.93; total reported value ≈ $14,875.
• Price basis: closing market price on 2026-09-17 (per filer).
• Shares owned after transaction: not reported in the provided filing details.
• Notable footnotes: (1) Issued under the non-employee director compensation policy in lieu of cash; (2) price based on 9/17/2026 closing price; (3) filer notes a managerial/partnership relationship with NEA entities and disclaims beneficial ownership to the extent indicated in that structure.
• Timeliness: The filing is marked late (transactionTimeliness = 'L'), which delays public disclosure of the trade.

Context

• This was an award of shares as director compensation (not an open-market buy or sale). Such awards are routine for non-employee directors and do not necessarily signal a personal purchase decision. The filing’s footnotes explain the compensation election and pricing method; one footnote addresses the filer’s relationship to certain NEA entities and a disclaimer of beneficial ownership.